J&J poised to establish no-strings-attached JLABS outside America

January 31, 2017 Christoph Graener

As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovation, JLABS, tells Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, that the company is actively looking to establish JLABS in Europe and Asia with an expectation that there will be news on this front in the near future.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Melinda Richter – Head of Johnson & Johnson Innovation, JLABS

Previous Article
Payer environment will impact biopharma prospects in 2017

Michael Hay, head of Informa Pharma Intelligence Products, shares his thoughts on how shareholder pressure ...

Next Article
Reinventing Arena to focus on Phase II clinical candidates

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus ...